PMID- 28485688
OWN - NLM
STAT- MEDLINE
DCOM- 20171122
LR  - 20171128
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 22
IP  - 10
DP  - 2017 Dec
TI  - Hepatitis B reactivation in patients receiving targeted therapies.
PG  - 592-598
LID - 10.1080/10245332.2017.1321882 [doi]
AB  - OBJECTIVES: Hepatitis B virus (HBV) reactivation may occur spontaneously, during 
      or after antiviral therapy, or when receiving immunosuppressive chemotherapy. HBV 
      reactivation has also been reported in cancer patients receiving targeted 
      therapies, such as monoclonal antibody and mammalian target of rapamycin (mTOR) 
      inhibitor. This review article is aimed to discuss the issue regarding chronic 
      HBV reactivation in patients receiving targeted therapies, with a special focus 
      on tyrosine kinase inhibitors. METHODS: Using MEDLINE search, the literature 
      relevant to hepatitis B reactivation, monoclonal antibody therapy and tyrosine 
      kinase inhibitor was reviewed. RESULTS: HBV-infected patients receiving tyrosine 
      kinase inhibitors (TKIs) may develop HBV reactivation even with resolved HBV 
      infection status. Although the exact mechanism of TKI-induced HBV reactivation 
      remains unclear, off-target immunological effects of TKI may play an important 
      role in contributing to HBV reactivation. DISCUSSION: Further well-designed 
      studies are necessary to find out the incidence and mechanism of HBV reactivation 
      in patients receiving TKIs. Screening, monitoring and prophylaxis or pre-emptive 
      antiviral therapy is mandatory in HBV patients who are going to receive 
      immunosuppressive therapy or targeted therapy. CONCLUSION: HBV reactivation may 
      occur in patients receiving monoclonal antibodies and TKIs, even with resolved 
      HBV infection status. Although the exact mechanism of TKI-induced HBV 
      reactivation remains unclear, off-target immunological effects of TKI may play an 
      important role in contributing to HBV reactivation.
FAU - Chang, Cheng-Shyong
AU  - Chang CS
AD  - a Division of Hematology and Oncology, Department of Internal Medicine , Changhua 
      Christian Hospital , Changhua City , Taiwan.
FAU - Tsai, Chien-Yu
AU  - Tsai CY
AD  - a Division of Hematology and Oncology, Department of Internal Medicine , Changhua 
      Christian Hospital , Changhua City , Taiwan.
FAU - Yan, Sheng-Lei
AU  - Yan SL
AD  - b Division of Gastroenterology, Department of Internal Medicine , Chang-Bing Show 
      Chwan Memorial Hospital , Lugang Township , Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20170509
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - 0 (Antiviral Agents)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Female
MH  - Hepatitis B/*drug therapy
MH  - Humans
MH  - Male
MH  - Protein Kinase Inhibitors/*therapeutic use
OTO - NOTNLM
OT  - Hepatitis B reactivation
OT  - immunological effects
OT  - monoclonal antibody
OT  - off-target
OT  - targeted therapy
OT  - tyrosine kinase inhibitor
EDAT- 2017/05/10 06:00
MHDA- 2017/11/29 06:00
CRDT- 2017/05/10 06:00
PHST- 2017/05/10 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2017/05/10 06:00 [entrez]
AID - 10.1080/10245332.2017.1321882 [doi]
PST - ppublish
SO  - Hematology. 2017 Dec;22(10):592-598. doi: 10.1080/10245332.2017.1321882. Epub 
      2017 May 9.